Ovid Therapeutics Inc.
OVID · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $2 | $23 | $22 | $66 |
| - Cash | $21 | $28 | $21 | $26 |
| + Debt | $1 | $14 | $14 | $15 |
| Enterprise Value | -$18 | $9 | $15 | $55 |
| Revenue | $0 | $6 | $0 | $0 |
| % Growth | -97.9% | 4,724.6% | 71.1% | – |
| Gross Profit | $0 | $6 | $0 | $0 |
| % Margin | 87.1% | 100% | 100% | 100% |
| EBITDA | -$12 | -$5 | -$12 | -$11 |
| % Margin | -9,197.7% | -79.3% | -9,545.4% | -14,160.5% |
| Net Income | -$12 | -$5 | -$10 | -$9 |
| % Margin | -9,210.6% | -74.7% | -7,873.1% | -12,175% |
| EPS Diluted | -0.17 | -0.066 | -0.14 | -0.13 |
| % Growth | -158% | 52.9% | -7.7% | – |
| Operating Cash Flow | -$13 | -$5 | -$10 | -$10 |
| Capital Expenditures | $0 | $0 | $0 | -$0 |
| Free Cash Flow | -$13 | -$5 | -$10 | -$10 |